India Glycols Ordered to Pay ₹32.95 Lakhs Customs Duty, Penalty
India Glycols Limited received an order confirming a customs duty demand of ₹32.95 lakhs and an equal penalty of ₹32.95 lakhs for its Ennature Bio-Pharma division. The issue relates to customs classification of imported goods between June 2020 and September 2024. The company plans to appeal and anticipates no material financial impact.
While the company states no material impact is anticipated and plans to appeal, the confirmed duty and penalty amount is substantial and represents a direct financial outflow.
The company has been ordered to pay a significant customs duty demand and penalty, which is a negative development.
India Glycols Limited has received an order from the Additional Commissioner, ACC (Import), NCH, New Delhi, concerning its Ennature Bio-Pharma division. The order, dated 18th December 2025 and received on 29th December 2025, confirms a customs duty demand of ₹32,95,005 for short-paid duty, along with applicable interest. Additionally, an equal penalty of ₹32,95,005 has been imposed under the Customs Act, 1962.
The issue pertains to the customs classification of certain goods imported by the company's Ennature Bio-Pharma division between June 2020 and September 2024. Despite the company submitting a detailed reply to the allegations, the adjudicating authority did not consider the submissions favorably and confirmed the duty demand and penalty. The company had previously deposited ₹32,96,284 towards duty and ₹11,22,338 as interest, totaling ₹44,18,622, under protest.
India Glycols Limited, based on its assessment and legal counsel's advice, believes it has a strong case on merits. The company intends to file an appeal and does not anticipate any material impact on its financial, operational, or other activities.
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.